Immuno-Oncology Partners

Immuno-Oncology Partners appears to be a small Belgian private company focused on healthcare-related advisory or other health-service activities rather than a drug-development biotech operating a therapeutic pipeline. Public business-registry sources identify it as a private limited company founded in 2020 in Belgium, with management-consulting and/or other health-services classifications. Available evidence does not indicate a disclosed proprietary drug pipeline, platform technology, clinical-stage asset portfolio, or public-market listing. Registry data further suggest the company has ceased operations or entered a stopped/dissolved status in 2026. As a result, it is best characterized as a healthcare-oriented advisory entity rather than a conventional immuno-oncology therapeutics developer.